13th, according to the most recent company presentation:...

13th, according to the most recent company presentation:

"Director participation • Medibio’s Australian directors who are eligible to take-up their entitlements intend to take-up their entitlements"

Now, let's see if THIS pans out.. At this rock bottom discount, let's see if the take up is just another token one, or a legitimately interested one from the australian directors.

As much as I have faith in our latest CEO appointment, I think he has quite an uphill battle to get us remotely where we would like to be. As tempted as I am to take up some of the entitlement offer - I am still torn - purely to average down my huge losses , in the hope that we see an acceptance from FDA on the 510 submission. And even then, who knows where this will take us and what this will achieve out there? Who also knows what else FDA has up their sleeve with the De Novo once they get more info from the company. A lot of ifs...

Another huge "if" is how many shareholders will actually take up their entitlement - personally I think that $4.05 m is looking very dicey. All of us are so much in the red and very disheartened at the deplorable outcome 2018 has been for Medibio. It is extremely hard if not impossible to keep positive these days.